Clinical Trial Update: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating liposomal doxorubicin plus cisplatin as palliative treatment for malignant pleural mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: National Institute of Cancerología | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: UNKNOWN